Last Updated: 4/24/21
On Friday, April 23, the CDC’s Advisory Committee on Immunization Practices (ACIP) met to discuss the pause on administration of the one-dose Johnson & Johnson/Janssen COVID-19 vaccine. Based upon a review of the data and evaluation of risk factors, ACIP has recommended that the pause be lifted immediately. Following this recommendation, the CDC and FDA lifted the pause and advised that use of the Johnson & Johnson/Janssen vaccine should resume.
We are awaiting guidance from the CDC on future allocations.
In the meantime, here is additional information from the FDA and CDC on the J&J vaccine...
The FDA has determined that the available data show that the vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older.
At this time, the available data suggest that the chance of thrombosis-thrombocytopenia syndrome (TTS) occurring is very low, but the FDA and CDC will remain vigilant in continuing to investigate this risk.
Health care providers administering the vaccine and vaccine recipients or caregivers should review the Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Fact Sheet for Recipients and Caregivers, which have been revised to include information about the risk of this syndrome, which has occurred in a very small number of people who have received the Janssen COVID-19 Vaccine.
Post Date: 4/16/21
Out of an abundance of caution, on Tuesday, 4/13, the CDC and FDA recommended a temporary pause in the administration of the Johnson & Johnson/Janssen (J&J) COVID-19 vaccine while the CDC investigates an extremely rare possible side effect.
In response to the recommendation, Rite Aid has paused the administration of all J&J vaccines and has worked to reschedule J&J vaccine appointments for customers to receive an alternative vaccine type.
Our primary concern is the health and safety of all of our customers, so we want to make sure you have the latest information from the CDC and FDA:
According to the CDC and FDA, as of April 12, more than 6.8 million doses of the J&J vaccine have been administered in the U.S.
The CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine.
All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination.
Right now, these adverse events appear to be extremely rare.
People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider.
If you received the vaccine a month or more ago, the risk of these events appears to be extremely low.
We expect updated guidance from the CDC and FDA soon. We are and will continue to follow their recommendations.
Visit CDC.gov for the latest information and to contact your health care provider if you have any questions or concerns. And as always, our pharmacists are there for you to help in any way they can.
To schedule an appointment or learn more, visit our COVID-19 vaccine page.